CD Biosynsis offers end-to-end Insect Cells Genome Editing and Metabolic Engineering Solutions, providing a complete platform for developing high-performance production strains for the Baculovirus Expression Vector System (BEVS). Insect cell lines (e.g., Sf9, Hi5) are the versatile host for producing complex recombinant proteins, VLPs, and vaccine antigens, requiring accurate folding and PTMs. Our solutions integrate cutting-edge CRISPR-based genome editing tools (KO, KI, BE, and CRISPRi) with rational design methodologies (metabolic modeling and high-throughput screening). We handle the entire engineering process, from initial target identification and pathway optimization to final strain stability validation, guaranteeing the rapid and successful development of Insect Cell lines for superior bioprocessing productivity and tailored product quality.
Get a QuoteOptimizing the Insect Cell/BEVS system requires managing the metabolic demands and stress imposed by the viral infection while ensuring the quality of the final product. Our platform ensures that modifications are strategically optimized to enhance folding capacity, minimize native proteolysis, and eliminate immunogenic insect glycans. By coupling precision genome editing with systematic analysis, we enable the rational development of strains that can stably produce complex molecules at high titers, managing the entire bioproduction pipeline from gene to product.
Comprehensive services covering all modifications: stable Knock-ins (KI) into safe harbor loci and multi-locus deletions (KO) via CRISPR-Cas9.
Multiplexed CRISPR strategies for simultaneous disruption of multiple genes (e.g., native glycoenzymes, proteases) to accelerate chassis development.
Base Editing (BE) & CRISPRi
Tools for fine-tuning: BE for single-nucleotide precision (promoter/chaperone tuning) and CRISPRi for reversible gene knockdown (viability genes).
Systematic optimization focusing on enhancing energy supply, managing viral stress, and boosting nucleotide sugar availability for PTMs.
Humanized Glycoengineering
Targeted editing of the glycosylation machinery (KO of insect PTMs, KI of human PTMs) to achieve human-compatible N-glycans for therapeutics.
Enhanced Folding & Assembly
Modification of ER-resident chaperones and folding catalysts to improve the yield and structural integrity of complex proteins and VLPs.
Computational prediction (CBM, Dynamic Modeling) and experimental verification (Fluxomics, Glycan Analysis) to guide rational design and MOI/TPI optimization.
High-yield, large-scale production and purification of recombinant proteins via BEVS, ensuring correct folding and structural integrity.
Rapid, automated high-throughput screening (HTS) and iterative optimization for isolating high-producer, stable monoclonal cell lines (MCB).
A seamless, project-based pathway from rational design to industrial strain readiness.
1. Rational Target Identification
2. Precision Genomic Modification
3. High-Throughput Phenotyping
4. Clone Verification & Delivery
Utilize metabolic modeling (Assay & Modeling) to analyze the Insect Cell/BEVS system and identify limiting factors (e.g., PTM capacity, post-infection viability).
Design a comprehensive strategy including KO of native PTMs, KI of human PTMs, and regulatory tuning targets for maximum product yield and quality.
Define HTS assay metrics for specific productivity ($\text{Q}_\text{p}$) and CQAs.
Apply optimized CRISPR-based tools (Genome Editing) to construct rationally designed strain variants or libraries.
Perform multi-gene knockouts (Multi-Gene Knockout) and stable chromosomal knock-ins of humanized pathways.
Ensure all edits are verified in the bulk population.
Select the lead clone based on titer, stability, and CQA analysis.
Genomic verification and stability testing of the final monoclonal cell line.
Delivery of the verified Insect Cell master cell bank (MCB) and all associated data.
Integrated Glycoengineering
Solutions integrate tools that target and resolve the primary BEVS limitation: non-human glycosylation, enabling the production of clinically relevant biotherapeutics and vaccine antigens.
BEVS Efficiency Optimization
Modeling and editing strategies are focused on enhancing the folding capacity and extending the viable, high-productivity phase post-viral infection for maximal yield.
Stable Monoclonal Lines
Focus on CRISPR/HDR integration into safe harbors and automated single-cell cloning ensures genetic stability, true clonality, and reliable performance.
Full Eukaryotic Toolset
Single-platform access to all necessary tools (Modeling, CRISPR, HTS, PTM Analysis) required for complex, high-titer recombinant protein development.
1. What makes Insect Cells the best host for complex protein solutions?
Insect cells are eukaryotic, supporting complex folding, assembly, and PTMs, and combined with the BEVS, they offer extremely high expression levels (up to g/L scale) at a cost-effective rate.
2. How do you ensure stable, long-term expression of engineered traits?
We use CRISPR/HDR to integrate the desired gene cassette (e.g., human glycosylation enzymes) into defined genomic safe harbor loci. This prevents gene silencing and ensures the modified traits are permanent and stable.
3. How is the optimal harvest time (TPI) determined and verified?
The optimal TPI is determined by Dynamic Kinetic Modeling and verified experimentally by measuring product titer and cell viability over time post-infection. This ensures harvest occurs just before significant cell lysis.
4. What is the role of HTS in Insect Cell line development?
HTS is crucial for rapidly screening engineered clones for high specific productivity ($\text{Q}_\text{p}$) and desired CQAs (e.g., correct glycosylation) in miniaturized culture systems, accelerating the selection of the best-performing monoclonal line.
5. Why is Multi-Gene Knockout needed in Insect Cells?
Multi-gene knockout is needed to systematically remove complex, redundant traits like multiple native host proteases or all alleles of key glycosylation genes (e.g., FUT, GNT) to ensure complete loss of undesirable function.
6. How do you ensure the final product quality (CQA)?
CQA control is achieved through Glycoengineering and targeted folding pathway modification. We use Glycan Analysis in the Assay phase to confirm that the editing strategy yields the optimal human-like N-glycan structure.
7. What input is required for a complete solutions project?
We require the specific recombinant protein sequence, the insect host cell line (Sf9/Hi5), and the primary optimization goals (e.g., humanized glycosylation, increase VLP yield, improve stability).
8. What is included in the final delivery package?
The final delivery includes the optimized Insect Cell master cell bank (MCB), a full report detailing all genomic modifications, stability data, and BEVS performance metrics (titer, viability, and CQA analysis).
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.